par Gillard, Pieter;Ling, Zhidong;Mathieu, Chantal;Crenier, Laurent ;Lannoo, Matthias;Maes, Bart;Roep, Bart;Gorus, Frans;Pipeleers, Daniel;Keymeulen, Bart
Référence Transplantation, 85, 2, page (256-263)
Publication Publié, 2008-01
Référence Transplantation, 85, 2, page (256-263)
Publication Publié, 2008-01
Article révisé par les pairs
Résumé : | One year survival of islet cell grafts has been reproducibly achieved under combination immune therapy including tacrolimus (TAC). However, the use of TAC causes beta-cell and renal toxicity. Because sirolimus (SIR) monotherapy was successful in kidney transplantation under antithymocyte globulin (ATG), we undertook a pilot study comparing SIR monotherapy with SIR-TAC combination therapy. |